Medicare Drug Price Setting Provides An Opportunity To Generate Stronger Evidence On Treatment Effect Heterogeneity | Health Affairs Forefront
To build public trust in the Medicare drug price-setting process, CMS must implement a more defined and transparent approach to collecting and using real-world evidence of treatment heterogeneity for underserved populations, thereby affirming its commitment to health equity.